Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

Phase 1positiveALLO-316Positive

AI Analysis

Summary

Allogene Therapeutics announced publication of Phase 1 TRAVERSE study results for ALLO-316, a CD70-targeting allogeneic CAR T therapy, demonstrating durable antitumor activity and remissions in advanced/metastatic renal cell carcinoma in the Journal of Clinical Oncology.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Outcome Details

Achieved robust expansion, tumor infiltration, and durable antitumor activity in solid tumor setting with first durable remissions following allogeneic CAR T

Importance:6/10

Sentiment:

0.75

CAR TAlloCAR Tsolid tumorsrenal cell carcinomapublicationdurable remissions

Related Companies

$ALLO

Read the original article

Published by GlobeNewswire Clinical Studies on July 15, 2026 12:30 PM

Read Original